Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 11/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21837518 | 1.00 | RNASEL (0.45) | RNASELENPP1P2RX3P2RX4P2RX2 | |
| SCHEMBL21837509 | 1.00 | RNASEL (0.45) | RNASELENPP1P2RX3P2RX4P2RX2 | |
| SCHEMBL21838003 | 0.92 | ENPP1 (0.52) | RNASELENPP1P2RX3P2RX4P2RX2 | |
| SCHEMBL21838006 | 0.92 | ENPP1 (0.52) | RNASELENPP1P2RX3P2RX4P2RX2 | |
| SCHEMBL21837853 | 0.90 | RNASEL (0.44) | RNASEL | |
| SCHEMBL21837846 | 0.90 | RNASEL (0.44) | RNASEL | |
| SCHEMBL21837858 | 0.90 | RNASEL (0.44) | RNASEL | |
| SCHEMBL21837569 | 0.89 | RNASEL (0.42) | RNASELENPP1 | |
| SCHEMBL21837482 | 0.89 | RNASEL (0.42) | RNASELENPP1 | |
| SCHEMBL21837717 | 0.89 | RNASEL (0.43) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | RNASEL 4339/4885ENPP1 2990/4885P2RX3 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.